Drugs and patents in ATC class C04AB - Imidazoline derivatives

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
ORAVERSE	phentolamine mesylate
PHENTOLAMINE MESYLATE	phentolamine mesylate
REGITINE	phentolamine mesylate
RYZUMVI	phentolamine mesylate
>Tradename	>Generic Name

Last updated: June 15, 2026

Executive summary: ATC C04AB (imidazoline derivatives, primarily topical vasodilatory/anti-erythema and related vasomotor indications) is a fragmented market with localized, product-level IP estates rather than a single dominant molecule. Patent risk is driven by (1) legacy small-molecule primary patents that have largely aged out in many geographies, (2) formulation and device-adjacent patents that can extend exclusivity, and (3) method-of-use and line-extension patents that vary by brand and region. Competitive entry typically occurs via ANDA/505(b)(2) for small-molecule generics and via licensing for branded reformulations; the highest remaining exclusivity value sits in specific branded dosing forms and combinations rather than the imidazoline chemotype itself.

H1: ATC C04AB imidazoline derivatives market dynamics and patent landscape (patents, exclusivity, generic entry risk)

Which imidazoline derivatives are used in ATC C04AB, and what are the key branded products?

ATC C04AB “imidazoline derivatives” is a therapeutic class that, in practice, is populated by a small set of imidazoline-containing agents used for vasodilatory indications (often topical or localized blood-flow modulation). The market structure is brand and formulation led: brands differentiate by strength, dosage form (cream/gel/solution/patch depending on jurisdiction), dosing regimen, and often by excipient systems that affect dermal delivery.

Practical market segmentation

Topical imidazoline vasodilators: typically compete on skin tolerability, onset of effect, spreadability, and vehicle technology.
Systemic imidazoline agents (where mapped to C04AB by some listings): compete on cardiovascular and autonomic safety profile, but in C04AB-specific commercial practice the market focus is generally localized vasodilatory therapy rather than centrally acting α-agonists.

Competitive landscape at the product level

Branded originator: tends to hold the earliest composition-of-matter and early process filings.
Follow-on players: often hold formulation, stabilization, penetration enhancer, and packaging patents.
Generic entrants: typically file once the reference listed drug’s primary patent and exclusivity periods have cleared, unless a later-listed formulation patent is still in force or listed in the applicable reference system.

Note: An “imidazoline derivatives” chemotype is broad. Patent landscapes are therefore product-specific (brand A’s imidazoline in cream differs from brand B’s imidazoline in gel, and from any combination product).

What patents protect ATC C04AB imidazoline derivatives: composition, formulations, methods of use, and manufacturing?

Patent protection for imidazoline derivatives in C04AB typically clusters into four buckets:

Composition of matter: the primary molecule

Early filings cover the imidazoline core substitutions and salts.
Later filings may cover specific isomers, specific salt forms, or narrow chemical sub-classes.

Commercial reality

Primary composition-of-matter tends to be the first to expire across major markets.
As a result, the “active” patent estate often shifts to secondary protection.

Formulation and vehicle technology: creams, gels, solutions, and topical delivery

Where the imidazoline derivative is used topically, formulation patents can be long-lived because they are tied to:

excipient systems (solubilizers, stabilizers)
viscosity and rheology
penetration enhancer selection and limits
controlled-release matrices
pH and buffering systems to maintain stability and tolerability
packaging constraints (oxygen/moisture barrier, container interaction)

Featured snippet style takeaway: For C04AB, formulation patents usually decide whether ANDA/505(b)(2) entry is blocked, not the imidazoline chemotype itself.

Method-of-use and dosing regimen patents

Common method-of-use themes include:

frequency and duration
patient subsets (e.g., disease severity strata or intolerance criteria)
combination regimens with other topical or systemic therapies
specific clinical endpoints (sometimes drafted as treatment “for” a condition, sometimes as a sequence)

Manufacturing and process patents

Process patents matter when:

stability drives special manufacturing steps
solvent selection or mixing order affects shelf-life
scale-up parameters or temperature constraints are claimed
sterilization/handling is required for certain dosage forms

When do ATC C04AB imidazoline derivative patents expire, and how do exclusivity periods affect launch timing?

For timing, two layers matter:

Patent expiry: the last expiring patent in the relevant jurisdiction (not just the first).
Regulatory exclusivity / data protection: where applicable, these can delay generic filings even after patent expiry or can add a separate barrier.

High-level timing pattern for legacy topical small molecules

Primary patents generally expire first.
Formulation patents may still be active 5 to 15 years later depending on filing dates and jurisdictional practice.
If the regulator lists formulation patents in the reference product’s status record, generic entrants face Paragraph IV-style challenges in markets that follow that framework.

Decision point for generic entry

Entry is generally blocked if an unexpired, listed patent covers the generic’s product form, strength, or an essential therapeutic instruction.

Because C04AB covers multiple products and jurisdictions, exclusivity timing cannot be stated as a single calendar without identifying a specific drug and jurisdictional listing.

How strong is the patent estate for ATC C04AB imidazoline derivatives: what makes patents enforceable or easy to design around?

Patent strength depends less on the existence of patents and more on whether claims are:

Product-shaping (must use that formulation component or device)
Trait-defining (must meet a functional parameter such as penetration depth, release profile, or stability)
Regimen-specific (must follow a dosing schedule that is part of the labeling)
Claim-breadth (broad claim scope blocks more competitors; narrow scope enables design-around)

Design-around vectors

Changing vehicle composition while matching API concentration.
Replacing penetration enhancers with non-infringing alternatives.
Using different salts or polymorphs where allowed.
Switching from immediate-release topical to controlled-release matrices (if permitted without infringing release-profile claims).
Reformulating to avoid claimed parameter ranges.

What generic entry risks exist for ATC C04AB imidazoline derivatives (Paragraph IV, FDA pathway, and litigation triggers)?

Generic entry risk is driven by the regulatory listing system and the claim scope of the last-in-force, listed patents.

Small-molecule generic pathways

ANDA (generic): requires showing bioequivalence and must respect patent carve-outs for any listed, relevant patents.
505(b)(2) (hybrid): often used for reformulations with partial reliance on existing data. Can still face patent challenges if the new product overlaps listed patent claims.

Bottlenecks

Listed formulation patents: commonly the final barrier.
Listed method-of-use patents: can force generic labels to “carve out” unapproved claims.

Common litigation triggers

Patent owner asserts that the proposed generic formulation infringes.
Patent owner asserts that the generic’s label induces infringement by practicing a claimed regimen.
Settlement agreements often include:
- “carve-out” label terms
- temporary supply restrictions
- non-admission clauses
- launch date commitments

Without a specific C04AB drug and its jurisdictional listing, it is not possible to identify the exact patent(s) asserted or the dates of any Paragraph IV challenges.

What patent litigation affects ATC C04AB imidazoline derivatives, and which settlements shape market entry?

For imidazoline derivative topical products, litigation typically focuses on:

formulation composition infringement
process infringement (mixing order, temperature regime, particle size in semisolid)
method-of-use labeling infringement

Settlement agreements in this category usually aim to:

fix an agreed launch date
narrow the generic label to avoid method-of-use infringement
permit generic manufacture under a defined product specification

Market impact

Settlements often convert uncertain litigation outcomes into predictable launch timing for investors and brand strategists.
The last settlement can also re-open the patent “bargaining” for later reformulations, because brand owners sometimes file new follow-on patents immediately after settling.

What is the Orange Book status of ATC C04AB imidazoline derivatives (listed patents and unexpired expiries)?

Orange Book status is drug-specific. ATC C04AB is a broad class and cannot be mapped to a single Orange Book set without identifying the specific approved products and their active ingredients.

Featured snippet style takeaway: Orange Book listing risk is determined by the drug’s reference product patent list, not the ATC class label.

How does C04AB imidazoline compare with other vasodilator classes in patent strategy and generic risk?

Relative to other vasodilator ATC subclasses:

C04AB often relies on formulation-level differentiation when topical delivery is central.
Some neighboring topical vascular classes rely more on device/combination patents; C04AB often relies more on vehicle and stability patents.
The generic entry risk profile in C04AB is typically higher for specific strengths/dosages than for the chemotype alone, because formulation patents are strength- and vehicle-specific.

Which formulations are protected by ATC C04AB imidazoline derivative patents (strength, base type, and delivery system)?

Formulation protection patterns typically map to:

specific base types (emulsion type, hydrogel vs ointment)
specific concentrations of penetration enhancers
specific pH ranges and buffers
specified release behavior parameters (for controlled-release topical forms)
stability in packaging conditions and shelf-life claims

Commercial implication

Generic products that match active concentration but differ in base can sometimes avoid infringement.
Generic products that copy the vehicle chemistry closely are more likely to face formulation infringement assertions.

Which companies own the most important ATC C04AB imidazoline patents, and what licensing deals matter?

Company ownership is product-specific and changes by geography. In C04AB, licensing typically occurs when:

originators license formulation technology to generic-ready partners for authorized generics
follow-on formulators license base technologies or controlled-release matrices
brand owners license their formulation patents to distributors for specific territories

Competitive implication

Authorized generics reduce litigation and preserve some revenue share for license holders, but can accelerate brand erosion if the authorized entrant is cost-competitive.

What manufacturing/IP barriers block generic imidazoline derivatives in C04AB?

Typical barriers include:

stability-driven process constraints (shelf-life, microbial control)
claimed critical process parameters in semisolid manufacturing
packaging components that interact with API stability
excipient sourcing constraints tied to claimed compositions

Entry friction

Even when patents expire on composition, manufacturing-process and formulation patents can keep entry risky if they remain in force.

Key takeaways

ATC C04AB imidazoline derivatives is a fragmented, product-level patent landscape; the chemotype alone does not predict exclusivity.
Remaining patent leverage is usually in formulation, method-of-use, and process claims for specific topical dosage forms and strengths.
Generic entry risk is highest where regulators list formulation or regimen patents and where claim scope is product-shaping rather than broadly chemical.
Litigation and settlements in this space typically convert contested formulation or labeling claims into fixed launch dates and label carve-outs, shaping the competitive curve.

FAQs

Which specific patents most often block generics of topical imidazoline derivatives in ATC C04AB?
Formulation and vehicle patents tied to topical delivery and stability, and any listed method-of-use patents that require a label carve-out.
Do formulation-only patent estates still prevent ANDA approval for imidazoline creams or gels?
Yes, if the formulation patents are listed and the proposed generic product falls within claim scope.
How do label “carve-outs” work for method-of-use patents covering imidazoline derivative therapy?
The generic label omits indications or instructions that would induce infringement of the claimed regimen.
What is the most common design-around path for imidazoline formulation patents?
Vehicle reformulation with different excipient systems and parameter ranges that avoid the claimed functional properties.
Does patent expiry automatically remove all barriers for a generic imidazoline derivative product?
No. Follow-on formulation, process, and regulatory exclusivity can remain the controlling constraints after primary patents expire.

References

European Medicines Agency. (n.d.). European public assessment reports and EPAR-related guidance.
U.S. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
U.S. FDA. (n.d.). 21 CFR Part 314: Applications for FDA approval to market a new drug.
U.S. FDA. (n.d.). Guidance for industry: Patent and exclusivity information submissions.

Drugs in ATC Class C04AB

Drugs in ATC Class: C04AB - Imidazoline derivatives

Market dynamics and patent landscape for ATC Class C04AB (imidazoline derivatives)